Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial
- PMID:33047868
- PMCID: PMC7702130
- DOI: 10.1111/liv.14633
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial
Abstract
Background & aim: An affordable, pangenotypic regimen remains as an unmet medical need for chronic hepatitis C patients in China. This single-arm, open-label, multicenter, phase 3 trial evaluated the efficacy and safety of coblopasvir, a pangenotypic non-structural protein 5A (NS5A) inhibitor, combined with sofosbuvir for treating Chinese patients with chronic hepatitis C virus (HCV) infection.
Methods: Treatment-naïve and interferon-experienced adult patients, including those with advanced fibrosis (F3) or compensated cirrhosis (F4), were treated with a universal, combinational regimen of coblopasvir 60 mg and sofosbuvir 400 mg, once daily, for 12 weeks. The primary efficacy endpoint was sustained virological response at post-treatment week 12 (SVR12).
Results: Overall, 371 patients (men, 51%; age, 47 ± 11 years; genotype 1a < 1%, 1b 48%, 2a 26%, 3a 6%, 3b 7% and 6 12%) were enrolled from 19 sites. Fifty-one patients (14%) had F3, 39 patients (11%) had F4 and 39 patients (11%) were interferon experienced. The overall SVR12 was 97% (95% CI, [94%, 98%]) for the full analysis set and was equal to or above 90% for all predefined subsets. Ten patients (3%) experienced virological relapse and two patients did not complete follow-up. No adverse events (AEs) occurred at a frequency ≥5%, and the most often reported AEs (≥1%) were neutropenia and fatigue. The majority of AEs were mild to moderate and transient without specific medical intervention.
Conclusions: The universal, pangenotypic combo of coblopasvir plus sofosbuvir is an efficacious and safe treatment for Chinese patients monoinfected with HCV of genotype 1, 2, 3 and 6, including those with compensated cirrhosis.
Lay summary: The regimen of coblopasvir and sofosbuvir is a safe and effective treatment for Chinese patients with genotype 1, 2, 3 and 6 HCV infection, including those with compensated cirrhosis. Therefore, this regimen would be a novel choice of treatment for this patient population.
Keywords: coblopasvir; pangenotypic regimen; safety; sofosbuvir; sustained virological response.
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Conflict of interest statement
Jing Ning, Hai Pan and Hong Qin were employees of Kawin Technology when executing this trial, and Li Li and Desheng Zhou are employees and stakeholders of Kawin Technology. The other authors have no conflict of interest to declare.
Similar articles
- Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, Mao Q, Jiang X, Wang C, Zhang Y, Jia J, Guo X, Li C, Ning J, Qin H, Pan H, Wei L.Rao H, et al.J Viral Hepat. 2020 Jan;27(1):45-51. doi: 10.1111/jvh.13208. Epub 2019 Oct 2.J Viral Hepat. 2020.PMID:31520460Clinical Trial.
- Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S.Andrieux-Meyer I, et al.Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16.Lancet Gastroenterol Hepatol. 2021.PMID:33865507Free PMC article.Clinical Trial.
- Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial.Kong F, Wen X, Wen X, Wang X, Wu G, Lin S, Wang L, Xing H, Yan X, Zheng S, Ning Q, Wang Z, Zhang L, Lin J, Tong Z, Huang C, Su M, Tong L, Jia J, Xin Y, Zhu Q, Wang J, Chen L, Li X, Wu X, Niu D, Liu Q, Wei W, Zhang Y, Li G, Niu J.Kong F, et al.J Gastroenterol Hepatol. 2021 Sep;36(9):2375-2382. doi: 10.1111/jgh.15412. Epub 2021 Feb 2.J Gastroenterol Hepatol. 2021.PMID:33491236Free PMC article.Clinical Trial.
- Daclatasvir: A Review in Chronic Hepatitis C.Keating GM.Keating GM.Drugs. 2016 Sep;76(14):1381-91. doi: 10.1007/s40265-016-0632-x.Drugs. 2016.PMID:27550544Review.
- Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.Chahine EB, Sucher AJ, Hemstreet BA.Chahine EB, et al.Ann Pharmacother. 2017 Jan;51(1):44-53. doi: 10.1177/1060028016668897. Epub 2016 Oct 1.Ann Pharmacother. 2017.PMID:27609942Review.
Cited by
- 'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment.Vo-Quang E, Pawlotsky JM.Vo-Quang E, et al.Gut. 2024 Aug 8;73(9):1570-1582. doi: 10.1136/gutjnl-2024-332177.Gut. 2024.PMID:38782565Free PMC article.Review.
- Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China.Wang X, Wei L.Wang X, et al.J Clin Transl Hepatol. 2021 Jun 28;9(3):419-427. doi: 10.14218/JCTH.2020.00097. Epub 2021 May 12.J Clin Transl Hepatol. 2021.PMID:34221928Free PMC article.Review.
- Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions.Bernal LA, Soti V.Bernal LA, et al.Cureus. 2023 Aug 22;15(8):e43924. doi: 10.7759/cureus.43924. eCollection 2023 Aug.Cureus. 2023.PMID:37614826Free PMC article.Review.
- Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: a systematic review and meta-analysis.Lei PK, Liu Z, Ung COL, Hu H.Lei PK, et al.BMC Gastroenterol. 2024 Sep 30;24(1):331. doi: 10.1186/s12876-024-03414-5.BMC Gastroenterol. 2024.PMID:39350091Free PMC article.
- Hepatitis C Knowledge and Self-Reported Testing Behavior in the General Population in China: Online Cross-Sectional Survey.Liu Y, Su J, Wang X, Xu H, Wang H, Kang R, Zheng L, Wang Y, Liu C, Jing Y, Zhang S.Liu Y, et al.JMIR Public Health Surveill. 2023 Dec 11;9:e39472. doi: 10.2196/39472.JMIR Public Health Surveill. 2023.PMID:38079213Free PMC article.
References
- Polaris Observatory HCV Collaborators . Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161‐176. - PubMed
- Rao HY, Li H, Chen H, et al. Real‐world treatment patterns and clinical outcomes of HCV treatment‐naive patients in China: an interim analysis from the CCgenos study. J Gastroenterol Hepatol. 2017;32(1):244‐252. - PubMed
- Wei L, Lim SG, Xie Q, et al. Sofosbuvir‐velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single‐arm, open‐label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127‐134. - PubMed
- Rao H, Song G, Li G, et al. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. J Viral Hepat. 2020;27(1):45‐51. - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous